Structure and function of GPCR heteromeric complexes in brain
Structure and function of GPCR heteromeric complexes in brain
批准号:
10252884
负责人:
Javier González-Maeso
金额:
$46.51万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-20 至 2024-06-30
关键词:
AffectAgonistAmberAnabolismAntidepressive AgentsBasic ScienceBehaviorBehavioralBiological AssayBrainBrain regionCell surfaceCellsChronic stressClinicalClinical ResearchClinical TrialsCodon NucleotidesCognitionComplexCoupledDataData SetDendritic SpinesDisease remissionDoseEndoplasmic ReticulumEventFamilyFluorescence MicroscopyG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsGoalsGrantHTR2A geneHallucinogensIn VitroIndividualInterventionKetamineMacromolecular ComplexesMajor Depressive DisorderMammalian CellMapsMediatingMediator of activation proteinMental DepressionMental disordersModelingMolecularMolecular AnalysisMoodsMorphologyMusNMDA receptor antagonistNeuronsPathway interactionsPatientsPeptidesPerceptionPharmaceutical PreparationsPharmacotherapyPhenotypePhenylalaninePopulationPositioning AttributeProcessPropertyProtomerPsyche structurePsychosesPublishingReportingRoleSensorySerotoninSerotonin Receptor 5-HT2ASignal TransductionStructureSynapsesSynaptic plasticityTestingTherapeuticTranslational ResearchTransmembrane DomainViralantidepressant effectbasecell typeclinical practicedensityfrontal lobemetabotropic glutamate receptor 2monoamineneural circuitnovelreceptorreceptor expressionrecombinase-mediated cassette exchangeresponseside effectsingle moleculestoichiometrytreatment strategyunnatural amino acids
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Major depressive disorder is a mental illness afflicting approximately 16% of the world population. Currently
available interventions including monoamine-based pharmacotherapies require several weeks to months for
beneficial effects to occur. In addition, these treatments are often accompanied by undesirable side effects.
Therefore, there is an urgent need for better antidepressant medications, with a faster onset of action, which will
also be effective in patients who do not respond to classical antidepressants. Recent clinical findings suggest
that psilocybin – a hallucinogenic serotonin 5-HT2A receptor (5-HT2AR) agonist, exerts fast-acting and long-lasting
antidepressant actions in patients suffering from major depression. Despite these striking effects, a number of
alterations in various mental domains, including sensory perception and thought processes, precludes the
routine use of psilocybin and other hallucinogens in daily clinical practice. G protein-coupled receptors (GPCRs)
are critical mediators of cell signaling. Although recognized as capable of activating G proteins in a monomeric
form, numerous studies reveal their possible association into hetero-oligomers, enabling allosteric crosstalk
between receptor protomers. We previously reported that 5-HT2AR and metabotropic glutamate receptor 2
(mGluR2) are able to interact physically to form a GPCR complex. Results from earlier versions of this R01 grant
showed that at least part of the cellular signaling and psychosis-like behaviors induced by hallucinogenic 5-
HT2AR agonists require expression of the 5-HT2AR-mGluR2 heteromer in the mouse frontal cortex. However, the
ability of cortical 5-HT2AR-mGluR2 to affect behavioral states associated with depression upon hallucinogen
administration remains to be elucidated. Similarly, as the functional importance of GPCR oligomerization remains
controversial, additional studies related to basic structural and signaling properties of the 5-HT2AR-mGluR2
complex are needed. Our published data and the preliminary data presented here support our working
hypothesis that inter-family GPCR heteromerization affects structure, sub-cellular localization and function of
both 5-HT2AR and mGluR2 in living mammalian cells. Our data are also consonant with the hypothesis that a
single dose of hallucinogenic 5-HT2AR agonists induces fast-acting and long-lasting effects on remission of
behavioral states associated with depression, and that these therapeutic-related phenotypes require expression
of 5-HT2AR and mGluR2 as a GPCR heteromer in the frontal cortex of mice. These data set the stage for a
uniquely comprehensive analysis of the molecular mechanism underlying the antidepressant effects of
hallucinogens, with the ultimate goal of developing safer, more effective, and non-hallucinogenic depression
treatment strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structure and function of the 5HT2A-mGlu2 heteromer in schizophrenia
-
批准号:8630649
-
项目类别:
-
资助金额:$42.25万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of the 5HT2A-mGlu2 heteromer in schizophrenia
-
批准号:8813306
-
项目类别:
-
资助金额:$36.86万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of the 5HT2A-mGlu2 heteromer in schizophrenia
-
批准号:9293907
-
项目类别:
-
资助金额:$36.2万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of the 5HT2A/mGluR2 complex in schizophrenia
-
批准号:7728021
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of the 5HT2A/mGluR2 complex in schizophrenia
-
批准号:7895696
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of the 5HT2A/mGluR2 complex in schizophrenia
-
批准号:8267620
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of the 5HT2A/mGluR2 complex in schizophrenia
-
批准号:8433427
-
项目类别:
-
资助金额:$40.27万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of GPCR heteromeric complexes in brain
-
批准号:10685601
-
项目类别:
-
资助金额:$46.51万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of GPCR heteromeric complexes in brain
-
批准号:10445344
-
项目类别:
-
资助金额:$46.51万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
Structure and function of the 5HT2A/mGluR2 complex in schizophrenia
-
批准号:8063085
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2009
-
负责人:Javier González-Maeso
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: